BIOMARIN PHARMACEUTICAL INC
No SEC Form 4 filings for $BMRN in the last 30 days.
BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results. Revenue rose 19.9% year over year to $989.7 million and exceeded analysts’ estimates by 6.5%. Full-year revenue guidance was $3.9 billion at the midpoint, 0.7% above estimates. Non-GAAP adjusted EPS was $1.20, 26.6% above consensus. The stock rose 3.7% to $63.75.
BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease-6aug26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Resul
BioMarin Pharmaceutical (BMRN) will report earnings Thursday after the bell. Last quarter, it posted revenue of $766.2 million, up 2.8% YoY, but missed analysts’ revenue and EPS estimates, while beating full-year EPS guidance. For the upcoming quarter, analysts expect revenue growth of 12.6% YoY. The article cites an average analyst price target of $87.92 versus $59.50.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BMRN (BIOMARIN PHARMACEUTICAL INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent BMRN coverage spans earnings, financial news and technology.
Results beat on revenue and non-GAAP EPS, with full-year revenue guidance slightly above consensus, supporting near-term upside bias but with margin pressure noted.
Guidance increase tied to VOXZOGO demand and additional regulatory/clinical catalysts (sNDA submissions, FDA acceptance, EU approval) support a constructive near-to-medium term risk/reward.
The article frames a near-term earnings catalyst for BMRN, but it does not add new fundamentals beyond expectations and prior-quarter context.
The deal expands BioMarin’s rare-disease pipeline with a first-in-disease ASO program, but it is preclinical and lacks clinical readouts or financial terms.
FDA acceptance of a supplemental NDA for full approval is a meaningful regulatory milestone that can re-rate VOXZOGO’s approval probability and commercial outlook.
alphai scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results. Revenue rose 19.9% year over year to $989.7 million and exceeded analysts’ estimates by 6.5%. Full-year revenue guidance was $3.9 billion at the midpoint, 0.7% above estimates. Non-GAAP adjusted EPS was $1.20, 26.6% above consensus. The stock rose 3.7% to $63.75.
4 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease-6aug26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Resul
6 min readBioMarin Pharmaceutical (BMRN) will report earnings Thursday after the bell. Last quarter, it posted revenue of $766.2 million, up 2.8% YoY, but missed analysts’ revenue and EPS estimates, while beating full-year EPS guidance. For the upcoming quarter, analysts expect revenue growth of 12.6% YoY. The article cites an average analyst price target of $87.92 versus $59.50.
3 min readBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said it entered a strategic collaboration and global exclusive license with the n-Lorem Foundation to develop an investigational antisense oligonucleotide targeting the RNU4-2 (n.64_65insT) variant for ReNU syndrome. The variant is estimated at about 75% of cases. BioMarin and n-Lorem will run preclinical studies and select a lead candidate for clinical trials. No approved medicines exist for ReNU syndrome.
4 min readBioMarin (BMRN) said the FDA accepted its supplemental NDA for VOXZOGO (vosoritide) to seek full approval for children with achondroplasia. The FDA set a PDUFA action date of Feb. 28, 2027. The filing relies on data from three ongoing studies measuring adult height and other growth outcomes. BMRN shares were $59.19, up 0.11% on the day.
2 min readBioMarin reported Q1 2026 revenue of $766 million on May 4 and raised full-year 2026 guidance to $3.825–$3.925 billion, about 20% year-over-year growth, citing the Amicus Therapeutics acquisition and added products (GALAFOLD, POMBILITI + OPFOLDA). The company also cited FDA approval of PALYNZIQ for adolescents, an sNDA for VOXZOGO, and pipeline updates. BioMarin said it secured ~$3.7 billion in non-convertible debt and had $221 million operating cash flow.
5 min readBioMarin Pharmaceutical reported positive Phase 3 results for VOXZOGO in children with hypochondroplasia, meeting the primary endpoint and showing statistically significant improvement in annualized growth velocity, with safety consistent with achondroplasia. The company plans to submit a supplemental NDA to the FDA in Q3 and file with the EMA. H.C. Wainwright reiterated a Neutral rating and set a $50 target.
4 min readMorgan Stanley strategist Todd Castagno said companies that initiate regular quarterly dividends have historically outperformed: 650 basis points on average over six months and 1,000 basis points over 12 months after announcements, according to his note. He screened for “dividend hopefuls” with no current quarterly payout, net cash >5% of market cap, and free cash flow yield >5%. Examples: Centene (18% FCF yield), BioMarin (10.4% FCF yield; revenue guidance $3.825–$3.925B), Duolingo (user shortf
6 min readHealthcare analysts have provided optimistic insights on InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN). Craig-Hallum maintained a Buy rating on InfuSystem Holdings with a significant upside, while J.P. Morgan initiated coverage on BioMarin Pharmaceutical with a Buy rating and a set price target. Both companies show strong analyst consensus ratings.
2 min readBioMarin Pharmaceutical Inc. has released new data regarding the long-term impact of its drug, Voxzogo (vosoritide), on children suffering from achondroplasia. The study focuses on how the treatment affects arm span, overall bone health, and growth development in these children. More detailed information requires registration on the MarketScreener website.
2 min read
